| Literature DB >> 20549494 |
Iuliana Oita1, Hadewych Halewyck, Bert Thys, Bart Rombaut, Yvan Vander Heyden, Debby Mangelings.
Abstract
Use of microfluidic devices in the life sciences and medicine has created the possibility of performing investigations at the molecular level. Moreover, microfluidic devices are also part of the technological framework that has enabled a new type of scientific information to be revealed, i.e. that based on intensive screening of complete sets of gene and protein sequences. A deeper bioanalytical perspective may provide quantitative and qualitative tools, enabling study of various diseases and, eventually, may offer support for the development of accurate and reliable methods for clinical assessment. This would open the way to molecule-based diagnostics, i.e. establish accurate diagnosis and disease prognosis based on identification and/or quantification of biomacromolecules, for example proteins or nucleic acids. Finally, the development of disposable and portable devices for molecule-based diagnosis would provide the perfect translation of the science behind life-science research into practical applications dedicated to patients and health practitioners. This review provides an analytical perspective of the impact of microfluidics on the detection and characterization of bio-macromolecules involved in pathological processes. The main features of molecule-based diagnostics and the specific requirements for the diagnostic devices are discussed. Further, the techniques currently used for testing bio-macromolecules for potential diagnostic purposes are identified, emphasizing the newest developments. Subsequently, the challenges of this type of application and the status of commercially available devices are highlighted, and future trends are noted.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20549494 PMCID: PMC7079953 DOI: 10.1007/s00216-010-3857-7
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Several commercially available microfluidics-based devices used for bio-analytical purposes a. Dynaflow System for ion-channel drug discovery (Cellectricon, Mölndal, Sweden); b. LC–MS microfluidics-based chip (Agilent, Santa Clara, CA, USA); c. Nanotiter plates (microfluidic ChipShop, Jena, Germany); d. 15-cycles continuous-flow polymerase chain reaction (PCR) chip (microfluidic ChipShop); e. 96-sample Sentrix Array Matrix (top) and the multi-sample Sentix Bead Chips (Illumina, San Diego, CA, USA); f. Disposable chip for generation of picoliter-volume droplets. Each droplet is further used as a PCR reactor (RainDance Technologies, Lexington, MA, USA)
Fig. 2Characterization of the scientific literature available on microfluidic devices. a. Yearly dynamics of the number of published papers b. Domains of interest for microfluidic devices research
Selected on-chip sample treatment using conjugated beads for affinity-based isolation of the target analyte
| No. | Target analyte | Tested sample | Capturing technique | Microfluidic device | Processed sample volume | Total time (isolation + separation) | Ref. |
|---|---|---|---|---|---|---|---|
| 1 | Dengue viruses | Clinical serum | Antibody-conjugated superparamagnetic bead | Microfluidic system with three integrated functional devices for pumping, mixing, and separation | 25 μL | 10 min | [ |
| 2 | West Nile virus | Sera from infected chicken | Microarray of probe molecules immobilized on a semipermeable membrane followed by extraction from the membrane using functionalized magnetic beads | Electrophoretic flow cell | 20 μL min−1 | 2–3 min | [ |
| 3 | Dengue virus serotype 2 and enterovirus (EV) 71 | Clinical serum | Antibody-conjugated superparamagnetic bead | PDMS chip integrating the sample purification/enrichment and RT-PCR diagnosis | 20–100 μL min−1 | 60 min | [ |
| 4 | Cholera toxin subunit B (CTB) | Solution | Antibody-conjugated superparamagnetic bead | PDMS chip integrating the sample purification/enrichment and detection | 100 μL | 60 min | [ |
| 5 | Peptides displayed on | A library of | Streptavidin-functionalized polystyrene microspheres | Continuous-flow microfluidic sorting device | >108 cells h−1 | [ | |
| 6 | gDNA from leukocytes | Human whole blood sample | Antibody-conjugated superparamagnetic bead | PDMS chip integrating the leukocytes purification, DNA extraction and fast analysis of genetic gene | 200 μL | 20 min | [ |
| 7 | Alpha-fetoprotein (AFP) | Spiked serum (0.1 μg mL−1) | Streptavidin-functionalized polystyrene microspheres | PDMS-glass hybrid immunoassay microchip | 100 μL min−1 | 55 min | [ |
| 8 | AFP, CEA, and PSA antigen | Solution, 10 ng mL−1 | Streptavidin-functionalized polystyrene microspheres | Multiplex electro-immunosensing system PDMS-glass hybrid | 90 μL | 55 min | [ |
| 9 | Alpha-fetoprotein (AFP) | Solution 1–1,000 ng mL−1 | Antibody-conjugated superparamagnetic bead | PMMA chips | 5 μL | 20 min | [ |
| 10 | Antibodies associated with an infection by the dengue virus (immunoglobulin G (IgG) and immunoglobulin M (IgM) | Serum | Virus-conjugated superparamagnetic bead | Integrated chip is composed of three polydimethylsiloxane layers and one glass layer | 100 μL | 30 min | [ |
| 11 | Pathogen-specific DNA | Whole blood spiked with Hepatitis B virus (HBV) and | Antibody-conjugated superparamagnetic bead | Centrifugal microfluidics on a polymer based CD platform | 100 μL | 12 min | [ |
Fig. 3a A photograph of assembled magnetic-bead-based microfluidic system performing on-chip single nucleotide polymorphism genotyping associated with genetic diseases. gDNA is extracted from leukocytes in the DNA extraction /PCR chamber. b A hand-held system including a microfluidic chip, an ASIC controller, a control circuit board, and EMVs has been developed. (Reproduced, with permission, from Ref. [26])
Fig. 4Integrated microfluidic device for RNA purification and real-time NASBA. a Photograph of the device. Each chip can perform two separate reactions with the same reagents, but different samples, to incorporate controls. b Single-device architecture showing the distinct functional microfluidic modules: RNA purification chamber (RPC) and real-time NASBA chamber. (Reproduced, with permission, from Ref. [59])
Selected on-chip PCR applications
| Objective | Chip architecture | Amplified sequence | Lowest concentration successfully amplified. | Detection of the amplified sequence | Ref. |
|---|---|---|---|---|---|
| Micro circulating PCR chip | Three bio-reactors with suction-type membrane and three microvalves operating at three different temperatures | 150 base pairs associated with the hepatitis C virus | 102 copies μL−1 | Off line after extraction from open reaction chambers after finishing the PCR procedure | [ |
| Concurrent electrochemical detection | Eleven parallel channels | 489-bp gene fragment | On-line, electrochemical, square-wave voltammetry | [ | |
| Extraction of genomic DNA and detection of single nucleotide polymorphism | Three major modules for rapid purification, DNA extraction and fast analysis of genetic gene | Genomic DNA from leukocytes | 33.26 ± 2.5 ng DNA μL−1 | Off-line, optical evaluation in UV | [ |
| Integration of PCR and CE on a single platform | Tri-layered glass-PDMS with integrated pneumatically-actuated valves and pumps for fluid handling, a thin-film resistive element that acts simultaneously as a heater and a temperature sensor, and channels for capillary electrophoresis (CE) | On-line, a laser diode and a charged coupled device (CCD) camera | [ | ||
| Detection of α-thalassemia-1 deletion using saliva samples | DNA extraction chamber, sample loading chamber, waste collection chamber, PCR reaction chambers | gDNA extracted from saliva | 12.00 pg μL−1 | Off-line, fluorescence, by an external optical detection module | [ |
| Device architecture for electrochemical patterning and detection of multiple DNA sequences | Amplicons diagnostic of human (H1N1) and avian (H5N1) influenza | 400 nmol L−1 | On-line integrated electrochemical array | [ | |
| Unsealed reactors for real-time isothermal helicase-dependent amplification | An array of 4 unsealed reactors for real-time helicase-dependent amplification | BNI-1 fragment of SARS cDNA | On-line fluorescence, CCD camera and image analysis | [ | |
| Quantitative PCR system for DNA amplification and detection | Two micro modules for thermal and microfluidic control with three serpentine-shape micropumps | 350 and 150-bp detection genes associated with two viruses, specifically hepatitis B virus (HBV) and hepatitis C virus (HCV), | 10 copies μL−1 | On-line fluorescence | [ |
| Fungal pathogenic nucleic acid detection | Microfluidic microarray assembly device on a CD-like glass chip | 0.5 nmol L−1 | On-line, confocal laser fluorescent scanner followed by image analysis | [ | |
| Single nucleotide polymorphism genotyping of PCR amplicons from whole blood | Thin film transistor photosensor integrating a microfluidic channel, a DNA chip platform, and a photodetector | Biotinylated target DNA | 0.5 nmol L−1 | On-line chemiluminescence photodetector | [ |
| Poly(methyl methacrylate) continuous-flow PCR microfluidic chip | Chip on the PMMA substrate with 20 parallel channels | DNA template with a 990-base pair fragment of | Off-line | [ |
Selected CE applications on a chip
| Analyte | Detection | Performance | Ref. |
|---|---|---|---|
| RT-PCR mixture obtained after amplification of a 234-base pair RNA isolated from a multiple mieloma cancer line | Laser-induced-fluorescence | Sufficient sensitivity even with dramatic reduction in instrument cost and complexity; separation resolution comparable with a benchtop, commercially available system; signal-to-noise ratio 32.3; LOD 0.1 ng μL−1 | [ |
| 8-Hydroxydeoxyguanosine (8-OH-dG) DNA adduct in urine (oxidative stress biomarker) | Electrochemically (amperometric detection) and via scanning electron microscope (SEM) imaging | LOD 20 attomoles; range from 100 nmol L−1–150 μmol L−1); separation efficiencies of approx. 120,000–170,000 plates m−1 | [ |
| DNA | Contactless conductivity measurement | High signal-to-noise ratio; label free detection | [ |
| Human rhinovirus serotype 2 (HRV2) | Fluorescence | Analysis time 10 s; purity assessment of fractions collected from size-exclusion chromatography purification of the labelling mixture and monitoring affinity complex formation | [ |
| Thrombin levels in plasma diluted to 10% ( | Fluorescence | Less than 1 min; run-to-run and chip-to-chip reproducibility (RSD) of migration times <10%; LOD 540 nmol L−1 | [ |
| AFP fluorescently labelled AFP in spiked serum samples | Fluorescence | Quantitative assay ; either the method of standard addition or a calibration curve; AFP at ng mL−1 levels in 10 μL human serum in a few tens of minutes | [ |
| K-ras oncogene for mutations highly associated with colorectal cancer | Fluorescence | Analysis time 11 min using the CAE system and 85 s for PMMA microchips | [ |
| α-Fetoprotein (AFP) from spiked serum samples | Laser-induced-fluorescence (LIF) | Total assay time <10 min; LOD 0.1 ng mL−1; CV <2%; quantitation range from 24 to 922 ng mL−1; good correlation of test results for 68 patient serum samples with a commercially available reference method | [ |
| Inactivated swine influenza | Fluorescence | Microchip-based concentration; separate the virus/fluorescent antibody complex from the unbound antibody electrophoretically; total assay time 6 min; <50 μL sample | [ |
| Human serum albumin (HSA) and its immunocomplex with a monoclonal antibody | Fluorescence | 800-fold signal enhancement; LOD 7.5 pmol L−1; analysis time 25 s | [ |
Fig. 5Schematic depiction of antibody fingerprinting using a microfluidic sorting device, cassette B (not to scale). Left: Micrograph of the sorting device in operation showing the first sorting stage. Right: Micrograph of the second stage at the collection point. (Reproduced, with permission, from Ref. [25])
Applications employing a detection method other than fluorescence
| Analyte | LOD | Detection | Ref. |
|---|---|---|---|
| α-Fetoprotein (AFP), hepato-cellular carcinoma biomarker | 0.1 ng | Electrochemical | [ |
| Thyroglobulin, cancer biomarker | 1 pg mL−1 | Surface plasmon resonance | [ |
| 8-Hydroxydeoxyguanosine (8-OH- dG) DNA adduct, biomarker for oxidative stress | 20 attomoles | Electrochemical | [ |
| Breast carcinoma markers | <7 fmol μL−1 | Nanoscale MS | [ |
| Prostate-specific antigen (PSA) | 0.08 μg L−1 | Electrochemical | [ |
| Nucleic acid sequences associated with Dengue virus serotype 2 | 30 picomolar | On-chip surface enhanced Raman spectroscopy (SERS) | [ |
| Urinary proteins (lysozyme, albumin) | 0.1 ppm | Electrochemical | [ |
| Trace level of AFP | 1 pg mL−1 | Electrochemical | [ |
| Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in human serum, liver disease biomarker | 0.145 μA U−1 L for ALT 0.463 μA U−1 for AST | Electrochemical | [ |
| Tumour markers | <0.5 μg L−1 | Electrochemical | [ |
| K-ras oncogene | 20 picomolar | SERS | [ |
| Insulin and albumin | 0.9 ng L−1 | SERS | [ |
| PSA | ∼Single molecule | SERS | [ |
| AFP | 2 ng mL−1 | Resonant microcantilever | [ |
| Hepatitis b surface antigen (hbsag) | <10 pg μL−1 | Surface acoustic wave | [ |
Fig. 6Biobar code assay developed for quantification of PSA in patient serum. Schematic representation of the PSA Au–NP probes (A) and the PSA bio-barcode assay (B). For details, see text (reproduced with permission from Ref. [166])
Molecular diagnostics FDA approved within the last three years (source: https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm, accessed 02.2010)
| Product Name | Marketing authorisation holder | Approval date | Application range | Working principle | Instrumentation | |
|---|---|---|---|---|---|---|
| 1 | VIDAS fPSA rt Assay | Biomerieux | 10/8/09 | Assessment of the chance that the man has prostate cancer based on measurement of free prostate-specific antigen (fPSA) | Two step enzyme immunoassay sandwich method with a final fluorescence detection | Ready-to-use reagent strips (10 wells/strip) to be used with benchtop chemistry analyzers |
| 2 | Architect Core | Abbott Laboratories | 04/10/09 | Detects antibodies (anti HBc) associated with the hepatitis B virus (HBV) core antigen in serum or plasma | Two-step immunoassay with chemiluminescence detection | Benchtop analyzer |
| 3 | Cervista HPV | Third Wave Technologies | 03/12/09 | Identify DNA from human papilloma virus (HPV) types 16 and 18 in cervical samples | DNA extracted from cervical samples is amplified in a thermal cycler. A second isothermal reaction will generate a fluorescent signal | Benchtop PCR |
| 4 | Cobas TaqMan | Roche Molecular Systems | 10/03/10 | Quantify the amount of hepatitis C viral RNA in a patient’s blood to help the physicians to determine an individual’s response to treatment | Nucleic acid (RNA) is separated from the cells in the blood sample. Separated RNA is amplified and the amount of HCV RNA in the patient’s blood is measured on the basis of the amount of light produced | Benchtop qPCR |
| 5 | Tspot. | Oxford Immunotec | 07/30/08 | Detect the immune response of thymus cells (T cells) found in an individual’s white blood cells that are stimulated by proteins produced by the bacteria that causes tuberculosis | Combination of a two step enzyme immunoassay sandwich method with a final visual detection | Benchtop-wells |
| 6 | Spot-Light HER2 CISH | Invitrogen | 07/01/08 | Measure the number of copies of Her-2 gene on chromosome 17 in breast cancer cells to assess if the patient is eligible for treatment with the cancer drug Herceptin (Trastuzumab). | On-slide binding of Her-2 gene with a matching digoxigenin-tagged DNA probe. A fluorescent (FITC) tagged antibody to digoxigenin followed by a horseradish peroxidase conjugated antibody to FITC and DAB further reveals the probes. | Fluorescence microscopy |
| 7 | xTAG respiratory viral panel (RVP) | Luminex Molecular Diagnostics | 01/03/08 | Identifies nucleic acids of multiple respiratory viruses in nasopharyngeal swab specimens from individuals suspected of respiratory tract infections | Multiplex detection of viral nucleic acids based on beads; selective isolation of viral RNA followed by PCR | Multiple steps, benchtop PCR equipment |
| 8 | Dako | Dako Denmark | 01/11/08 | Assessment of the risk of post-surgical recurrence of breast cancer and long-term survival based on the measurement of the number of copies of the TOP2A (Topoisomerase 2 alpha) gene on chromosome 17 in breast cancer cells | On slide binding of Her-2 gene with a matching a red fluorescent-tagged DNA probe binds to matching DNA of the TOP2A gene and a green fluorescent-tagged DNA probe binds to the matching central portion of chromosome 17 in cells on the slide | Fluorescence microscopy |
| 9 | GeneSearch BLN Test | Veridex LLC | 07/16/07 | Rapid detection of metastases larger than 0.2 mm in lymph nodes tissue removed from biopsies of breast cancer patients | Chemical amplification of two gene products abundant in breast tissue and scarce in lymph node cells. Fluorescence detection | Benchtop PCR |
| 10 | Mesomark | Fujirebio Diagnostics | 01/24/07 | Assessment of metastases for a rare cancer of the internal body lining (mesothelioma) | Colorimetric reaction for specific protein fragments released by cells of malignant mesothelioma into a patient’s blood | Benchtop analyzer |
| 11 | MammaPrint | Agendia Laboratory | 2009 | Assess a patient’s risk of distant breast cancer metastasis | Microarray-based gene expression analysis of RNA extracted from breast tumour tissue | Benchtop–bioanalyzer |
| 12 | AVantage A/H5N1 flu test | Arbor Vita | 04/01/09 | Rapid diagnostic test for the H5N1 influenza A viral subtype (avian or bird flu) | Rapid proteomics test for the specific detection of H5N1 | Portable |
Fig. 7a Gartner hype cycle model (reproduced with permission). b Evolution of percentage change in the number of papers published yearly on microfluidics